[Elite_video_player id="1"]

Leave a Reply

Your email address will not be published. Required fields are marked *

Dr Siv Kjølsrud Bøhn

Associate professor, Norwegian University of Life Sciences


Siv Kjølsrud Bøhn (PhD) is Associate professor at Norwegian University of Life Sciences. Her current scientific focus on improving health via impacting the gut microbiota. Bøhn participates in various clinical trials across different patient populations, mainly taking the responsibility of trial- design and implementation and outcomes ranging from the microbiota-effects, molecular biomarkers, to method validations and measures of fatigue and health-related quality of life. Bøhn has teaching and supervision expertise within nutrition, public health, cell biology, biotechnology, and immunology.

Bøhn has a solid background molecular effects of diet interventions in different patient populations with hands-on experience from clinical trial design, trial implementation and biobanking, biomarker profiling of inflammation and gene expression analysis as well as statistics and bioinformatics.


Introducing the gut microbiota – why do we have bacteria in our guts and why are they important for health?

On all bodily surfaces that are exposed to the environment we find a complex and diverse ecosystem of microorganisms (bacteria, viruses, fungi, and protozoa), collectively termed the microbiota. During the last decades it has become clear that the microbes in the gut (‘the gut microbiota’), are serving many beneficial roles for our health and that disturbances in the gut microbiota are associated with the development of many different diseases. During evolution we have adapted to co-exist with the microbes using efficient strategies to keep the microbes in check in the mucosal linings. At the same time, the microbes help us to digest ‘left-over’ food components that are otherwise indigestible to us. The products of bacterial metabolism in the gut not only provide energy, but also serve other roles such as regulating the immune responses. However, we are only at the beginning of understanding how the gut microbiota and their metabolic products affect our health.

The lecture will introduce the microbiota and broadly explain why we have bacteria in our guts, what they are doing there, how we control them, how they are affected by the food that we eat and why disturbances in the microbiota may lead to diseases of various kinds.


Prof. Konstantinos Gerasimidis

Professor of Clinical Nutrition, University of Glasgow


Professor Konstantinos Gerasimidis is Professor of Clinical Nutrition. He has graduated in Nutrition and Dietetics and completed his postgraduate studies in Clinical Nutrition. During his doctoral research at the University of Glasgow, he explored the effect of exclusive enteral nutrition on the gut microbiota and nutritional status of children with Crohn’s disease; Professor Gerasimidis also leads a laboratory team which explores the role of gut microbiota and its interaction with diet in the onset, propagation, and management of acute and chronic conditions. He has a strong interest in exploring the effect of habitual diet, elimination diets and artificial nutritional support on the gut microbiota of children and adults with inflammatory bowel disease.


In the human gut resides a complex microbial community whose size is at least equal to that of the human body eucaryotic cells, but with a functional capacity which outnumbers that of the host by a number of 100. Recent evidence suggests that this microbial community, often named as the gut microbiome, is important not only for the onset of infectious disease but also for the development of non-communicable conditions, including conditions of the digestive tract. Diet is a major regulator of the human gut microbiome composition and function. However, the role of diet in the causal pathway between the gut microbiome and gastrointestinal disease can be complex. For example, in patients with coeliac disease, it is unclear if the gut microbiome plays a role in the underlying disease pathogenesis, or any changes observed are the effects of treatment with gluten free diet. Likewise, beneficial members of gut microbiome, like Bifidobacteria, have been implicated in the aetiology of irritable bowel syndrome (IBS), but treatment of active IBS symptoms with a low FODMAP diet further decreases the concentration of these species, and interventions with probiotics have had modest only effects. An exciting area of future research is whether we can use microbial signatures as prognostic markers of adverse disease outcomes in conditions, like intestinal failure, and also if dietary manipulation of the gut microbiome can control disease activity outcomes in patients with Crohn’s disease and ulcerative colitis.

Prof. Amandine Everard

Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), UCLouvain, Université catholique de Louvain, Brussels, Belgium


Amandine Everard is a researcher associate from the FNRS (Fonds National de la Recherche Scientifique) at UCLouvain in Brussels, Belgium. She is professor and leading a researcher group studying the roles of gut microbes in the regulation of host metabolism and food intake at the Louvain Drug Research Institute.

She is author of more than 50 research publications in that field and her work is internationally recognized as she is part of the Highly Cited Researcher over the world.


Gut microbes: a promising therapeutic target for obesity and type-2 diabetes?

The gut microbiota is a key player involved in health and diseases. Gut microbes have been identified as important regulators of host metabolism. Therefore, different tools targeting the gut microbiota such as probiotics, are studied to reduce obesity and metabolic disorders. Probiotics have a long history of use even if a clear definition only emerged at the end the twentieth century. The more commonly exploited species are lactobacilli and bifidobacteria. Over these last years, other genus were also proposed as potential beneficial microbes and are referred as next-generation beneficial bacteria candidates. Among the potential next-generation beneficial bacteria that are under investigation in the context of obesity, Akkermansia muciniphila seems to be a promising candidate. Akkermansia muciniphila is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. We demonstrated that this bacterium was able to counteract diet-induced obesity and metabolic disorders in mice. Nowadays, a large body of evidence also demonstrates the causal beneficial effects of Akkermansia muciniphila in several preclinical models. In order to translate these preclinical data into human applications, we administered this bacterium in volunteers suffering from overweight and metabolic syndrome. This study demonstrates that pasteurized Akkermansia muciniphila was safe and well tolerated in humans. Moreover, this first exploratory study reveals that Pasteurized Akkermansia muciniphila has also protectives effects on the deleterious progression of the metabolic syndrome over time in humans. In conclusion, these results support the interest of targeting gut microbes to counteract metabolic disorders.